Clinical Trials
17 trialsA Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
Institute of Hematology & Blood Diseases Hospital, China
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
University of Michigan Rogel Cancer Center
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Charite University, Berlin, Germany
ACITAC-001
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The General Hospital of Western Theater Command
Allogeneic UCB-derived CAR-T for B-ALL
The General Hospital of Western Theater Command
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine
PACER
Ann & Robert H Lurie Children's Hospital of Chicago
PACMAN
Princess Maxima Center for Pediatric Oncology
ZJU-HSCT-INO
First Affiliated Hospital of Zhejiang University
JUVENTAS-ALL05
First Affiliated Hospital of Zhejiang University
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Peking University Third Hospital